Results
1 -
10 of
12BTK Inhibitors: Focus on Ibrutinib and Similar Agents, Resistance of Targeted Therapies Excluding Antibodies for Lymphomas Evolution of CLL treatment u2014 from chemoimmunotherapy to targeted and individualized therapy, Nature Reviews Clinical Oncology Acalabrutinib: First Global Approval, Drugs Targeting B Cell Signaling in Chronic Lymphocytic Leukemia, Current Oncology Reports Frontline Therapy of CLL: Evolving Treatment Paradigm, Current Hematologic Malignancy Reports Pitfalls of Combining Novel Agents in Lymphoma, Current Treatment Options in Oncology Targeted Therapy in Chronic Lymphocytic Leukemia (CLL), Current Hematologic Malignancy Reports What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?, Current Treatment Options in Oncology Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor, Journal of Hematology & Oncology Second-generation inhibitors of Bruton tyrosine kinase, Journal of Hematology & Oncology